Transdermal H2S sensing device for monitoring peripheral artery disease
Ended Project Grant Awarded Last action
- Award ID
- SB1HL121871
- Recipient
-
Exhalix, LLC UEI C1NVZ5M6E319
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $500,000
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- New Mexico, USA
Award details come from USAspending.gov.
Description
- Abstract
- Peripheral artery disease (pad) and small vessel disease (SVD) are the consequences of damage to the endothelial cells that line all vessels, leading to inadequate skin perfusion, end-organ failure, and limb damage. This damage is prevalent in the diabetic patient population where nearly 50% suffers from pad and SVD. Numerous studies describe the difficulties of diagnosing vascular disease in diabetic patients, either due to limited access to the cost-prohibitive transcutaneous oximetry (TCPO2), lack of accuracy in limb blood flow evaluation using ankle brachial index (ABI), or the high risk of kidney damage with the use of invasive angiography. The proposed effort addresses this unmet need by offering a simple, inexpensive, and effective device ideal for widespread clinical use to detect and follow the course of pad and SVD. The expected socioeconomic impacts of clinical adoption of the proposed technology include improvement in patient quality of life by delaying or preventing the development of debilitating disease and a decrease in patient care costs. Our diagnostic system utilizes hydrogen sulfide (H2S), a newly described endothelium-derived vasodilator, that decreases with the onset of endothelial damage and dysfunction. Importantly, normal production of H2S is essential for endothelial function, for improving recovery from muscle ischemia, and to mitigate damage from myocardial and kidney infarction. The technology, transdermal arterial gasotransmitter sensor (tags™), employs an innovative gas-phase detector which noninvasively measures trace levels of H2S emitted from the skin as a measure of vascular health in the skin. During a nhlbi-funded phase II sbir research effort, tags™ measurements were carried out in human subjects to assess local vascular and microvascular health in healthy individuals, asymptomatic T2D patients, and symptomatic T2D patients with limb-threatening wounds undergoing lower-extremity revascularization surgery. IT was found that tags™ signals correlate inversely with atherosclerotic and cardiovascular risk score, ascvd, and with HGBA1C and LDL/HDL ratio (i.e., the biomarkers of diabetes). The results also reveal that pad in diabetes decreases the bioavailability of H2S in the lower extremity (leg) skin of patients with diabetes so that tags™ readings can assess the severity of skin microvascular disease. The proposed CRP pre-clinical study is intended to engage more clinicians to test the tags™ methodology against other measures of vascular health and to increase the size of each cohort to provide appropriate power for statistical evaluation. Successful completion of the CRP effort by meeting our specific aims is expected to lead to phase IIB clinical studies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $500,000 |
Quick answers
Who received award SB1HL121871?
SB1HL121871 was awarded to Exhalix, LLC by National Heart Lung and Blood Institute (National Institutes of Health) on August 15, 2022.
How much is award SB1HL121871 worth?
$500,000 has been obligated on SB1HL121871.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award